Should guideline panels declare nonfinancial conflicts of interest?  by Tugwell, Peter & Knottnerus, J. André
Journal of Clinical Epidemiology 67 (2014) 1179e1180EDITORIAL
Should guideline panels declare nonfinancial conflicts of interest?Nonfinancial (eg, intellectual) conflicts of interest are
felt by some to be as important as financial conflicts. Others
worry that if more extensive criteria for potential conflict of
interest are used as exclusion criteria, this will lead to
everyone with vital content experience being excluded.
Three articles in this issue debate this issue. Akl et al.
assessed the presence of both types on an American Col-
lege Chest Physicians guidelines panel and argue that
restrictions on participation in guideline panels should
include the nonfinancial conflicts of interest. Viswanathan
et al. offer a way to systematize this and operationalize this
into defined decision options ranging from disclosure fol-
lowed by no change in the systematic review team or activ-
ities, through inclusion on the team along with other
members with differing viewpoints to ensure diverse per-
spectives and exclusion from certain activities or from the
project entirely. As Bero points out in her nice Commentary
with telling examples, such an expansion has merits but
does run the risk of invading an individual’s privacy and
making it difficult to validate.
Multimorbidity often interfaces with complex interven-
tions because the interventions in such cases are frequently
no longer simple. With the aging population, multimorbid-
ity will be an increasing challenge in clinical epidemiology
[1,2]dit is challenging to conceptualize and operationalize;
Muth et al. have done this and report on a pilot of their in-
teraction matrix method in patients with heart failure with
an informative table demonstrating exactly how they
handled the different comorbidities and identified the clini-
cal management issues.
What is the best way of conceptualizing and evaluating
complex interventions? Journal of Clinical Epidemiology
has published a number of articles on multicomponent and
complex interventions [3] reflecting the interest and range
of strong opinions in this area. However, it is true that
there is lack of consensus on the best way forward, so
the article summarizing a literature search and semistruc-
tured interviews by Guise et al. under the aegis of the
Agency for Healthcare Research and Quality Evidence-
based Practice is welcome; a framework is provided
with a proposed checklist of critical reporting items that
we hope will provide a focus for forging a consensus in
this area.
Diagnosis features in two articles. Searching for system-
atic reviews of diagnostic tests has not been as easy as
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Open access under CC BY-NC-ND license.of therapy, so it will be a pleasant surprise if the conclu-
sions of van Ernst et al. are born out, that Medline searches
are sufficient and other databases do not need additional
searching in many instances. Heterogeneity is critically im-
portant when seeking to combine results in any meta-
analysis and indeed is more complex in assessing diagnos-
tic tests than in assessing interventions as sensitivity and
specificity both need combining but are usually correlated.
Naaktgeboren et al. review the options and propose a
checklist of items to consider and report on when exploring
sources of heterogeneity in diagnostic reviews.
Instrumental variables are increasingly recommended
over traditional methods such as ordinary least squares
for analyzing quasiexperimental studies to reduce un-
measured confounding. Boef et al. caution that the sample
size is often too small to provide this benefit and provide
an equation for approximation of the threshold sample
size, above which instrumental variable estimates are
preferred.
Cross-cultural validation of common questionnaires, so
that they can be used in and compared across different pop-
ulations, is all too often done only using direct translation
by computer rather than by humans. Therefore, it is refresh-
ing to see the article by Ritter and Lorig demonstrating sim-
ilar consistency and validity including responsiveness,
performance characteristics for the Spanish version of their
Self-Efficacy to Manage Chronic Disease Scale.
Two of the most popular assessment schemata for
Guidelines are the GRADE Guideline Assessments [4]
and the AGREE [5] assessment; Hazelwood et al. in re-
viewing guidelines for the management of rheumatoid ar-
thritis show that many do not meet either of these and,
furthermore, that because these two differ from each other,
the result also differs.
Incentives work! This is no surprise, but it is good to see
it documented in a systematic review of nine randomized
trials for the increasingly prevalent electronic surveys as re-
ported here by David and Ware.
Finally, two letters expand on options for using distribu-
tion curves as outcomes for public health interventions.
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